Global Community

When investors look at the Malaysian construction and property sectors, giants like MRCB or Berjaya Corporation often dominate the conversation. However, peering into the micro-cap space often reveals hidden value.Read more

Investment Thesis DefenCath's regulatory moat (only FDA-approved antimicrobial CLS in the U.S., NCE+GAIN exclusivity through 2033, composition patent to 2042) is intact and the 72% real-world CRBSI reduction is standard-of-care quality data; the TDAPA pricing step-down is a commercial mechanics event, not a competitive displacement event The stock at $7.02 prices in approximately the bear case ($6.54), meaning investors are effectively receiving the REZZAYO prophylaxis Phase III binary and the DefenCath TPN pipeline for free — an unusual asymmetry for a cash-flow-positive commercial pharma company Operating cash flow of $175M in FY2025 and $148.5M in cash provides full self-funding of pipeline without dilution risk, and the $75M buyback at current prices represents management's explicit capital allocation conviction about intrinsic value The Melinta acquisition was well-priced ($30M goodwill on $391M identified intangibles) and adds an annualizing $130M+ revenue stream with shared call points that provide SG&A leverage as the combined platform scales Post-TDAPA recovery in 2027 (3x–5x higher add-on payment vs. H2 2026 per management, plus Medicare Advantage contracting upside not in guidance) provides a clearly identified catalyst path back to re-rating independent of pipeline success Risk Considerations ReSPECT Phase III failure (data Q2 2026) would eliminate ~$221M of base case rNPV, trigger impairment of the $143M IPR&D intangible, and likely reset the stock to the $5.60 52-week low or below — this is the primary binary risk and is near-term Customer concentration at 79% revenue from three accounts is structurally dangerous; any publicly announced reduction in DefenCath orders from a major dialysis organization would be a material negative event with little warning The Q4 GAAP EPS miss ($0.16 vs.Read more

Lucid Diagnostics' EsoGuard is a novel screening tool for esophageal cancer. It is relatively non-invasive and may become widely accepted soon.Read more

Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more

NCT Alliance Berhad (“NCT”) has entered a new phase in its corporate journey with the appointment of Mr Ong Chou Wen as Chief Executive Officer, effective 1 April 2026. The leadership change comes at a meaningful juncture for the property developer, as the market continues to reward companies that can combine project execution, balance sheet discipline, and sharper commercial positioning in an increasingly competitive operating environment.Read more

Rating: Speculative Buy / High Risk Style: AI infrastructure “picks-and-shovels” growth name Core debate: Is AAOI a genuine bottleneck asset in AI networking, or a cyclical optics supplier temporarily enjoying peak demand and peak multiples? Executive view Applied Optoelectronics is no longer just a small-cap optical component company.Read more

很多公司会讲未来、讲愿景、讲故事。 但真正敢去申请 从 ACE 转去 Main Market 的公司，其实已经不是单靠讲故事了。 Sorento Capital 这次正式提呈转主板申请，本身就是一个很明显的信号：公司对自己的基本面、盈利能力和未来发展，是有信心的。 因为主板不是你想转就能转，能够走到这一步，代表公司认为自己已经具备更高层次上市平台的条件。Sorento 也表示，转板预计可在 2026年第三季 完成，前提是取得相关监管与股东批准。 为什么说这是“信心”而不是“形式”？ 因为公司这次不是空手去申请。 Sorento 过去三个财政年，也就是 FY2023 到 FY2025 ，累计净利达到 RM75.6 million ，其中 FY2025 单年净利 RM26.24 million 。同时，公司保留盈利、营运现金流和整体财务条件也都已达到主板要求。讲白一点，Sorento 现在不是“希望市场给机会”，而是它已经有数据、有利润、有基础去争取主板定位。 如果再看最新业绩，其实更能看出这家公司底子不差。 截至 2025年12月31日 的 1HFY2026 ，Sorento 录得大约 RM91.3 million 营收，虽然按年小跌，但 PAT 却增长 39% 左右至 RM16.0 million 至 RM16.7 million ，第二季单季净利约 RM8.67 million ，而且公司还宣布派发 0.5 sen interim dividend 。这说明什么？说明它不是靠营收硬撑，而是在成本控制、营运效率和盈利质量上开始做出来。 这种公司，市场通常一开始不会太快看懂。因为 ACE 市场的股票，很多时候天然会被打折看待。无论是机构关注度、市场定位、还是估值逻辑，都会比较保守。但一旦公司启动转主板，市场就会开始重新问一个问题： 这家公司，到底还应不应该继续用 ACE 小票的方式来估值？ Sorento 本身做的业务也不是难懂的故事型业务。 它主营的是 浴室和厨房卫浴产品 ，包括水龙头、洗手盆、浴缸、按摩浴缸等，属于比较实在、需求长期存在的消费建材类业务。这样的公司，本来就比较适合走“稳盈利、稳现金流、稳扩张”的路线，而不是靠题材炒一轮就散。 所以这次转主板申请，我反而觉得市场不应该只把它看成一则普通企业公告。 更应该把它看成公司向市场释放的一个态度：我们已经不满足于做一只 ACE 股，我们准备进入下一个阶段。 这种主动升级，本身就代表公司对自己的成长、财务实力和资本市场定位是有底气的。 再从估值角度看，这里也有一点值得注意。 截至最近市场数据显示，Sorento 股价大约在 RM0.68-RM0.69 区间，市值约 RM593 million，对应 P/E 大约19倍。虽然现阶段估值已不算早期水平，但若后续转主板顺利推进，市场认可度、资金关注度及估值框架同步提升，那么 Sorento 未来仍不排除存在进一步价值重估、甚至估值继续向上的可能。 简单来说，Sorento 现在最值得留意的地方，不只是转主板这件事本身，而是： 它敢申请转主板，代表公司认为自己已经准备好了。 而一旦市场也开始接受这一点，估值逻辑就可能慢慢改变。 简单结论 Sorento 这次申请转主板，不只是程序动作，更像是一种“公司对自己基本面有信心”的公开表态。 三年累计盈利已经达到主板门槛，最新半年净利继续增长，还有股息，说明它已经不是一般那种只靠题材支撑的 ACE 股。 所以如果市场接下来慢慢开始把 Sorento 当成“准主板股”来看，那它真正值得关注的，可能就不只是现在的股价，而是 接下来会不会迎来一轮更合理的价值重估。Read more

When fuel costs stay high or become more volatile, the effect usually goes beyond just higher transport bills. Over time, it also pushes households, businesses and property owners to look more seriously at alternatives that can reduce long-term operating costs.Read more

Rating: Buy / Quality Compounder with Cyclical Entry Risk Style: Infrastructure-led industrial compounder Core debate: Is Prysmian still “just a cable manufacturer,” or has it become a scarce, strategic infrastructure platform leveraged to electrification, grid bottlenecks, and AI-era connectivity? Executive view Prysmian is one of the highest-quality ways to invest in the physical backbone of electrification and digitalization.Read more